"Characterization of First-line Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors in Metastatic Breast Cancer among Florida Health Care Systems." by Reshma Mahtani

Article

Characterization of First-line Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors in Metastatic Breast Cancer among Florida Health Care Systems.

Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting (2020)

Reshma Mahtani, Baptist Health South Florida

Link

Abstract

Reshma L. Mahtani, Luis E. Raez, Jessica Unzaga, Jorge J García, Krupa Paranjpe, Irene Arias, Aurelio Bartolome Castrellon

Disciplines

Medicine and Health Sciences

Publication Date

2020

Citation Information

Reshma Mahtani. "Characterization of First-line Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors in Metastatic Breast Cancer among Florida Health Care Systems." Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting Vol. 38 Iss. Supplement (2020)
Available at: http://works.bepress.com/reshma-mahtani/37/